Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;205(1):5-16.
doi: 10.1007/s10549-023-07222-5. Epub 2024 Jan 24.

Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?

Merel E van de Loo  1 , Layla Andour  1 , Anne E van Heesewijk  1 , Hendrika M Oosterkamp  2 , Gerrit-Jan Liefers  3 , Marieke E Straver  4
Affiliations
Review

Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?

Merel E van de Loo et al. Breast Cancer Res Treat. 2024 May.

Abstract

Background: Patients with locally advanced endocrine positive tumors who will not benefit from chemotherapy can be treated by either primary surgery or neoadjuvant endocrine therapy (NET). How often does NET result in breast-conserving surgery (BCS)?

Methods: We conducted a literature search in PubMed and Embase, to identify articles on surgical treatment after NET.

Results: In 19 studies the pathological complete response (pCR) rate was reported after NET; an overall pCR rate of 1% was found. Compared with neoadjuvant chemotherapy (NCT), the BCS rate was significantly higher after NET (OR 0.60; 95% CI, 0.51-0.69; P < 0.00001). The surgical conversion rate was reported in eight studies [4-75.9%], with a mean of 30.2%.

Conclusion: This review found that one out of three patients becomes eligible for BCS after treatment with NET.

Keywords: Breast cancer; Breast conserving surgery; Neoadjuvant endocrine treatment.

PubMed Disclaimer

References

    1. Burstein HJ et al (2010) American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract 6(5):243–246 - PubMed - PMC
    1. Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6 - PubMed - PMC
    1. Perloff M, Lesnick GJ (1982) Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg 117(7):879–881 - PubMed
    1. Schick P et al (1983) Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 22(4):278–282 - PubMed
    1. Fisher B et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7):2483–2493 - PubMed

MeSH terms

Substances

LinkOut - more resources